A label update for the insomnia drug Belsomra (suvorexant) C-IV adds study findings on its use in treating insomnia in patients with mild-to-moderate Alzheimer’s disease, drugmaker Merck announced.
CODAC Health Recovery & Wellness Inc. has established a service site with 24-hour access to support for patients with opioid use disorder.
Medicare beneficiaries continue to experience limited access to evidence-based treatment for opioid use disorder, at a time when prescription opioid misuse among older adults remains a major concern.
As children diagnosed with attention-deficit/hyperactivity disorder transition into adolescence and young adulthood, primary care providers are missing the mark in monitoring them for several important health risks, a study warns.
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress conference.
Christoph U. Correll, MD, discusses the results of the ENLIGHTEN‑2 study, which compared weight gain and cardiometabolic side effects in patients taking olanzapine and patients taking olanzapine plus samidorphan.